Neil Joyce Goldstein

US Patent:

6365157, Apr 2, 2002

Filed:

Sep 22, 1999

Appl. No.:

09/401163

Inventors:

Patricia Rockwell - West Readding CT
Neil I. Goldstein - Maplewood NJ

Assignee:

ImClone Systems, Inc. - New York NY

International Classification:

A01N 3718

US Classification:

4241561, 4241381, 4241431, 514 2, 435330, 435334

Abstract:

Monoclonal antibodies that specifically bind to an extracellular domain of a flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.

US Patent:

6413717, Jul 2, 2002

Filed:

Mar 18, 1998

Appl. No.:

09/040981

Inventors:

Yilong Sun - Fort Lee NJ
Paul B. Fisher - Scarsdale NY
Neil I. Goldstein - Maplewood NJ

Assignee:

Corixa Corporation - Seattle WA

International Classification:

C12Q 168

US Classification:

435 6, 435 912

Abstract:

Methods are provided for identifying agents that modulate the expression of genes, such as genes encoding tumor suppressor or tumor-promoting proteins. The methods generally comprise screening candidate agents for the ability to enhance expression of a tumor suppressor gene, such as mda-7, or for the ability to inhibit expression of a tumor-promoting gene within a cell. Modulating agents may be used, for example, within anti-cancer therapies.

US Patent:

6875741, Apr 5, 2005

Filed:

Sep 24, 2001

Appl. No.:

09/962756

Inventors:

Renuka Pillutla - Bridgewater NJ, US
Renee Brissette - Edison NJ, US
Arthur J. Blume - Annandale NJ, US
Lauge Schäffer - 2100-DK Copenhagen Ø, DK
Jakob Brandt - 2700-DK Broenshoej, DK
Neil I. Goldstein - Maplewood NJ, US
Jane Spetzler - 2100-DK Copenhagen Ø, DK
Søren Østergaard - 2700-DK Broenshoej, DK
Per Hertz Hansen - 2800-DK Lyngby, DK

International Classification:

C07K007/06
A61K038/17

US Classification:

514 12, 514 2, 514 3, 514 13, 514 17, 530300, 530303, 530326, 530330

Abstract:

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.

US Patent:

7056679, Jun 6, 2006

Filed:

Oct 24, 2002

Appl. No.:

10/280066

Inventors:

Renuka Pillutla - Bridgewater NJ, US
Renee Brissette - Clarksburg NJ, US
Michael Spruyt - Mahwah NJ, US
Olga Dedova - Highland Park NJ, US
Arthur Blume - Annandale NJ, US
John Prendergast - Lawrenceville NJ, US
Neil Goldstein - Maplewood NJ, US

Assignee:

Antyra, Inc. - Edison NJ

International Classification:

G01N 33/53

US Classification:

435 71, 435 6, 435 5, 435 4, 435DIG 17, 435DIG 15, 536 234, 536 231, 536530, 536300

Abstract:

The invention relates to a modified phage display method for detecting and identifying target and target binders. The modified methods involve transforming host cells with two separate phages of a target or target library and a target-binder library, and selecting to eliminate the non-paired targets and binders. The invention also relates to antibodies that bind to complexes of target and target binders; nucleic acids encoding target and target binders peptides; and the use of sequence information inherent in the targets and target binders for target validation using in silico approaches. The invention further relates to diagnostics and therapeutics employing the disclosed target and target binder peptides or polynucletides and their use in small molecule drug discovery; diagnostic and therapeutic applications directed to cancers and similar disorders; and site directed assays for high throughput drug screening.

US Patent:

7060808, Jun 13, 2006

Filed:

Jun 7, 1996

Appl. No.:

08/973065

Inventors:

Neil I. Goldstein - Maplewood NJ, US
Nicholas A. Giorgio - New York NY, US
Steven Tarran Jones - Radlett, GB
Jose William Saldanha - Enfield, GB

Assignee:

ImClone Systems Incorporated - New York NY

International Classification:

C07H 21/04

US Classification:

536 231, 536 2353, 5303873, 53038885, 435 691, 435 696, 435325, 4352523

Abstract:

A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.

US Patent:

7173005, Feb 6, 2007

Filed:

Sep 24, 2002

Appl. No.:

10/253493

Inventors:

Renuka Pillutla - Bridgewater NJ, US
Olga Dedova - Highland Park NJ, US
Arthur J. Blume - East Greenwich RI, US
Neil I. Goldstein - Maplewood NJ, US
Renee Brissette - Clarksburg NJ, US
Pinger Wang - North Brunswick NJ, US
Hao Liu - Pennington NJ, US
Michael Lennick - Exton PA, US
Paul Fletcher - Cheshire CT, US

Assignee:

Antyra Inc. - Edison NJ
Novo Nordisk A/S - Bagsvaerd

International Classification:

C07K 7/06
A61K 38/17

US Classification:

514 12, 514 2, 514 3, 514 17, 530300, 530330

Abstract:

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.

US Patent:

20030224001, Dec 4, 2003

Filed:

Feb 25, 2003

Appl. No.:

10/374600

Inventors:

Neil Goldstein - Maplewood NJ, US
Nicholas Giorgio - New York NY, US
Steven Jones - Radlett, GB
Jose Saldanha - Enfield, GB

International Classification:

A61K039/395
C07H021/04
C07K016/30
C07K016/46

US Classification:

424/178100, 530/388800, 530/391100, 536/023530

Abstract:

Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.

US Patent:

20030236190, Dec 25, 2003

Filed:

Sep 24, 2002

Appl. No.:

10/253471

Inventors:

Renuka Pillutla - Bridgewater NJ, US
Renee Brissette - Edison NJ, US
Arthur Blume - Annandale NJ, US
Lauge Schaffer - Copenhagen O, DK
Jacob Brandt - Broenshoej, DK
Neil Goldstein - Maplewood NJ, US
Jane Spetzler - Copenhagen O, DK
Soren Ostergaard - Broenshoej, DK
Per Hansen - Lyngby, DK

International Classification:

A61K038/23

US Classification:

514/012000

Abstract:

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.

Address:

131 Rensselaer Rd, Essex Fells, NJ 07021

Phone:

9733799114

VIN:

WBAEK13547CN83787

Make:

BMW

Model:

6 SERIES

Year:

2007